Navigation Links
VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
Date:5/14/2009

Comprehensive Phase 2 Program Combines Histology, Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of Action and Positive Impact on Vascular Inflammation

SAN FRANCISCO, May 14 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed enrollment in a Phase 2 clinical trial of its lead drug, VIA-2291 in patients who have experienced an acute coronary syndrome event such as a heart attack or unstable angina. The randomized, double blind, placebo-controlled study examines the impact of VIA-2291 on plaque inflammation as measured by Positron Emission Tomography with fluorodeoxyglucose tracer (FDG-PET), as well as other standard biomarkers of inflammation, over 24 weeks following such an acute event. A total of 52 patients have been enrolled in the study, which is expected to report data in the second half of 2009.

VIA-2291 is designed to be a selective and reversible inhibitor of 5 Lipoxygenase, a key enzyme in the biosynthesis of leukotrienes, which are important mediators of inflammation believed to be involved in the development and progression of atherosclerosis. The FDG-PET study is the third Phase 2 clinical trial of VIA-2291 conducted by the Company in cardiovascular disease. In addition to being generally well-tolerated, earlier studies reported at the American Heart Association 2008 Scientific Sessions in November 2008, and the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2009 in May 2009, suggest multiple effects of the drug on inflammation, as measured through histology, biomarkers and advanced imaging. These include:

  • Significant, dose dependent, inhib
    '/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
2. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
3. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
5. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
6. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
7. Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
8. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
9. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
11. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 19, 2014 Sales Horizons, a ... its online sales skills training course to ... , MedTech clinical staff spend the majority of their ... standalone medical center, or physician practice – providing support ... why stop there? Sales Horizons believes clinical staff are ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... 18, 2014 According to ... Research "Life Science Reagents Market(Products- PCR Reagent Kits, ... In-Vitro Diagnostic Reagents and Others; End Users- Commercial ... Laboratories, and Forensic Laboratories)- Global Industry Analysis, Size, ... the global life science reagents market was valued ...
(Date:8/18/2014)... China is increasingly being recognized ... research industry. Clinicaltrial.gov statistics highlight the popularity of ... population; a high increase in infectious diseases; a ... pool of patients and a track record of ... China also presents challenges for the clinical research ...
Breaking Biology Technology:Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2
... March 20 On Wednesday, April 29, 2009, Wyeth (NYSE: ... 2009 first quarter. The Company will hold a forty-five minute ... on April 29, 2009. Interested investors and others may ... through our Internet webcast, which may be accessed by visiting ...
... Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased ... agreement with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) ... to Lifeline Biotechnologies for a combination of stock, ... Endoscopy originally purchased the products from Lifeline Biotechnologies ...
... has shown that certain marginalized groups including the ... African Americans and Latinos fare worse than others ... injuries and fatalities. , Now, a ... that they also experience greater terrorism-related fears and make ...
Cached Biology Technology:Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings 2Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc. 2Disabled and other vulnerable groups more susceptible to terrorism fears 2
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s ... Meet the Philippine tarsier: a tiny, adorable and downright "cool" ... animals that Americans are familiar with," said Rafe Brown, curator-in-charge ... giant eyes and ears; an extremely cute, furry body; a ... interesting expanded fingers and toe tips that look a bit ...
(Date:8/19/2014)... a new implantable tissue scaffold coated with bone growth ... When applied to bone injuries or defects, this coated ... that looks and behaves just like the original tissue. ... dramatic improvement over the current standard for treating bone ... the patient,s body a painful process that does ...
(Date:8/19/2014)... ( Aug. 19, 2014 ) -- Scientists at the ... pick up and transfer single cells using a pipette ... They describe this engineering feat and preliminary test results ... the American Chemical Society . , "Studying single cells ... current biomedical research," said nanomedicine department. faculty member Lidong ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Engineering new bone growth 2Engineering new bone growth 3Moving single cells around -- accurately and cheaply 2
... NY-- A multinational team of scientists has identified a single gene, ... fruit and seeds of the oil palm are the source of ... provide one of the most promising sources of biofuel. ... high-quality full genome map of the oil palm plant and to ...
... in California,s Central Valley, one of the world,s most ... species miles from farmland. Writing in Environmental Toxicology ... Tree Fogs in remote mountain areas, including national parks; ... by the elements. California,s Central Valley is one ...
... The following statement is being issued by Robbins Geller Rudman & Dowd ... Litigation SUPERIOR COURT OF THE STATE OF CALIFORNIA ... IN RE PACIFIC BIOSCIENCES OF CALIFORNIA , INC. SECURITIES ... OF PROPOSED SETTLEMENT OF CLASS ACTION Hon. Marie S. Weiner ...
Cached Biology News:Full genome map of oil palm indicates a way to raise yields and protect rainforest 2Full genome map of oil palm indicates a way to raise yields and protect rainforest 3Pesticides contaminate frogs from Californian National Parks 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 4
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
...
... Clone/PAD: ZMD.440. Immunogen: Synthetic peptide derived ... PDGF-D (platelet derived growth factor D iris-expressed ... which differs from mouse and rat by ... with the ~50 kDa human mouse and ...
Biology Products: